메뉴 건너뛰기




Volumn 37, Issue 12, 2014, Pages 3286-3293

Impact of islet autoimmunity on the progressive β-cell functional decline in type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCAGON; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN CLASS 2; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

EID: 84911865268     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0961     Document Type: Article
Times cited : (43)

References (38)
  • 1
    • 70449394029 scopus 로고    scopus 로고
    • Pancreatic islet in flammation in type 2 diabetes: From α and β cell compensation to dysfunction
    • Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet in flammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009;115:240-247
    • (2009) Arch Physiol Biochem , vol.115 , pp. 240-247
    • Ehses, J.A.1    Ellingsgaard, H.2    Böni-Schnetzler, M.3    Donath, M.Y.4
  • 5
    • 84894580064 scopus 로고    scopus 로고
    • Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes
    • Butcher MJ, Hallinger D, Garcia E, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 2014;57:491-501
    • (2014) Diabetologia , vol.57 , pp. 491-501
    • Butcher, M.J.1    Hallinger, D.2    Garcia, E.3
  • 6
    • 34247170807 scopus 로고    scopus 로고
    • Interleukin-1-receptor antagonist in type 2 diabetes mellitus
    • Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526
    • (2007) N Engl J Med , vol.356 , pp. 1517-1526
    • Larsen, C.M.1    Faulenbach, M.2    Vaag, A.3
  • 7
    • 42449137013 scopus 로고    scopus 로고
    • The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus
    • Donath MY, Mandrup-Poulsen T. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab 2008;4:240-241
    • (2008) Nat Clin Pract Endocrinol Metab , vol.4 , pp. 240-241
    • Donath, M.Y.1    Mandrup-Poulsen, T.2
  • 9
    • 0030175880 scopus 로고    scopus 로고
    • Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes
    • Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9:379-383
    • (1996) J Autoimmun , vol.9 , pp. 379-383
    • Verge, C.F.1    Gianani, R.2    Kawasaki, E.3
  • 10
    • 0032534668 scopus 로고    scopus 로고
    • Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes
    • Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998;161:6963-6969
    • (1998) J Immunol , vol.161 , pp. 6963-6969
    • Naserke, H.E.1    Ziegler, A.-G.2    Lampasona, V.3    Bonifacio, E.4
  • 11
    • 0031953634 scopus 로고    scopus 로고
    • Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes
    • Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998;47:733-742
    • (1998) Diabetes , vol.47 , pp. 733-742
    • Kawasaki, E.1    Yu, L.2    Rewers, M.J.3    Hutton, J.C.4    Eisenbarth, G.S.5
  • 12
    • 0003137572 scopus 로고
    • Predicting IDDM: Use of humoral immune markers
    • Palmer JP. Predicting IDDM: use of humoral immune markers. Diabetes Rev 1993;1:104-115
    • (1993) Diabetes Rev , vol.1 , pp. 104-115
    • Palmer, J.P.1
  • 13
    • 0022570021 scopus 로고
    • Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis
    • Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237-241
    • (1986) Diabetes , vol.35 , pp. 237-241
    • Groop, L.C.1    Bottazzo, G.F.2    Doniach, D.3
  • 14
    • 0028258126 scopus 로고
    • Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
    • Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303
    • (1994) Diabet Med , vol.11 , pp. 299-303
    • Zimmet, P.Z.1    Tuomi, T.2    Mackay, I.R.3
  • 15
    • 0034799480 scopus 로고    scopus 로고
    • Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes
    • Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001;50:1008-1013
    • (2001) Metabolism , vol.50 , pp. 1008-1013
    • Juneja, R.1    Hirsch, I.B.2    Naik, R.G.3    Brooks-Worrell, B.M.4    Greenbaum, C.J.5    Palmer, J.P.6
  • 16
    • 0027229335 scopus 로고
    • Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients
    • Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993;16:902-910
    • (1993) Diabetes Care , vol.16 , pp. 902-910
    • Gottsäter, A.1    Landin-Olsson, M.2    Fernlund, P.3    Lernmark, A.4    Sundkvist, G.5
  • 17
    • 39749160476 scopus 로고    scopus 로고
    • The islet autoantibody titres: Their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus
    • van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 2008;25:117-125
    • (2008) Diabet Med , vol.25 , pp. 117-125
    • Van Deutekom, A.W.1    Heine, R.J.2    Simsek, S.3
  • 18
    • 17844393918 scopus 로고    scopus 로고
    • Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with metabolic control (UKPDS 70)
    • Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005;48:695-702
    • (2005) Diabetologia , vol.48 , pp. 695-702
    • Davis, T.M.1    Wright, A.D.2    Mehta, Z.M.3
  • 19
    • 0031560175 scopus 로고    scopus 로고
    • UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
    • Turner R, Stratton I, Horton V, et al.; UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997;350:1288-1293
    • (1997) Lancet , vol.350 , pp. 1288-1293
    • Turner, R.1    Stratton, I.2    Horton, V.3
  • 20
    • 17844403542 scopus 로고    scopus 로고
    • IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)
    • Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005;48:703-708
    • (2005) Diabetologia , vol.48 , pp. 703-708
    • Bottazzo, G.F.1    Bosi, E.2    Cull, C.A.3
  • 21
    • 33750594322 scopus 로고    scopus 로고
    • Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: Results of a blinded controlled study
    • Seyfert-Margolis V, Gisler TD, Asare AL, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006;55:2588-2594
    • (2006) Diabetes , vol.55 , pp. 2588-2594
    • Seyfert-Margolis, V.1    Gisler, T.D.2    Asare, A.L.3
  • 22
    • 70350534475 scopus 로고    scopus 로고
    • Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes
    • Herold KC, Brooks-Worrell B, Palmer J, et al.; Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009;58:2588-2595
    • (2009) Diabetes , vol.58 , pp. 2588-2595
    • Herold, K.C.1    Brooks-Worrell, B.2    Palmer, J.3
  • 23
    • 0030589224 scopus 로고    scopus 로고
    • Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins
    • Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996;157:5668-5674
    • (1996) J Immunol , vol.157 , pp. 5668-5674
    • Brooks-Worrell, B.M.1    Starkebaum, G.A.2    Greenbaum, C.3    Palmer, J.P.4
  • 24
    • 0035871763 scopus 로고    scopus 로고
    • Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes
    • Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001;166:5265-5270
    • (2001) J Immunol , vol.166 , pp. 5265-5270
    • Brooks-Worrell, B.1    Gersuk, V.H.2    Greenbaum, C.3    Palmer, J.P.P.4
  • 25
    • 65049083839 scopus 로고    scopus 로고
    • Improved T cell assay for identification of type 1 diabetes patients
    • Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods 2009;344:79-83
    • (2009) J Immunol Methods , vol.344 , pp. 79-83
    • Brooks-Worrell, B.1    Warsen, A.2    Palmer, J.P.3
  • 27
    • 34547605312 scopus 로고    scopus 로고
    • T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes
    • Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007;56:2110-2115
    • (2007) Diabetes , vol.56 , pp. 2110-2115
    • Goel, A.1    Chiu, H.2    Felton, J.3    Palmer, J.P.4    Brooks-Worrell, B.5
  • 29
    • 84872166396 scopus 로고    scopus 로고
    • Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients
    • Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013;171:164-170
    • (2013) Clin Exp Immunol , vol.171 , pp. 164-170
    • Brooks-Worrell, B.M.1    Palmer, J.P.2
  • 30
    • 0032940245 scopus 로고    scopus 로고
    • Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients
    • Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999;48:983-988
    • (1999) Diabetes , vol.48 , pp. 983-988
    • Brooks-Worrell, B.M.1    Juneja, R.2    Minokadeh, A.3    Greenbaum, C.J.4    Palmer, J.P.5
  • 31
    • 84855185039 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2012
    • American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
    • (2012) Diabetes Care , vol.35 , pp. S11-S63
    • American Diabetes Association1
  • 33
    • 79952279727 scopus 로고    scopus 로고
    • Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: Efforts to harmonize procedures among the laboratories
    • Bingley PJ, Williams AJ, Colman PG, et al.; T1DGC. Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials 2010;7(Suppl.):S56-S64
    • (2010) Clin Trials , vol.7 , pp. S56-S64
    • Bingley, P.J.1    Williams, A.J.2    Colman, P.G.3
  • 34
    • 56649115489 scopus 로고    scopus 로고
    • Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    • Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
    • (2008) Diabetes Care , vol.31 , pp. 2188-2192
    • Sosenko, J.M.1    Palmer, J.P.2    Rafkin-Mervis, L.3
  • 35
    • 84899074071 scopus 로고    scopus 로고
    • CD8 T cell reactivity to islet antigens is unique to type 1 while CD4 T cell reactivity exists in both type 1 and type 2 diabetes
    • Sarikonda G, Pettus J, Phatak S, et al. CD8 T cell reactivity to islet antigens is unique to type 1 while CD4 T cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun 2014;50:77-82.
    • (2014) J Autoimmun , vol.50 , pp. 77-82
    • Sarikonda, G.1    Pettus, J.2    Phatak, S.3
  • 36
    • 33846126592 scopus 로고    scopus 로고
    • Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity
    • Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 88-92
    • Wang, J.1    Miao, D.2    Babu, S.3
  • 37
    • 36448978896 scopus 로고    scopus 로고
    • Type 1 diabetes as a relapsing-remitting disease?
    • von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-994
    • (2007) Nat Rev Immunol , vol.7 , pp. 988-994
    • Von Herrath, M.1    Sanda, S.2    Herold, K.3
  • 38
    • 79959704370 scopus 로고    scopus 로고
    • HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion
    • Williams RC, Muller YL, Hanson RL, et al. HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion. Diabetologia 2011;54:1684-1692
    • (2011) Diabetologia , vol.54 , pp. 1684-1692
    • Williams, R.C.1    Muller, Y.L.2    Hanson, R.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.